Rexahn Pharmaceuticals, Inc. Awarded Patent in Japan for Novel Anti-cancer Isoquinolinamine Compounds
7/9/2013 10:15:37 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing potential best-in-class oncology therapies, today announced that the Japan Patent Office has granted Patent No. 5270564 covering a series of novel isoquinolinamine compounds, their pharmaceutical composition, and method for producing an anti-tumor effect.
Help employers find you! Check out all the jobs and post your resume.
comments powered by